Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Omeros Corp OMER

Healthcare
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of... see more

Recent & Breaking News (NDAQ:OMER)

Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results

Business Wire April 1, 2024

Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024

Business Wire March 27, 2024

Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy

Business Wire February 20, 2024

Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust

Business Wire February 1, 2024

Omeros Corporation Reports Third Quarter 2023 Financial Results

Business Wire November 9, 2023

Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023

Business Wire November 6, 2023

Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy

Business Wire November 3, 2023

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Business Wire November 2, 2023

Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer

Business Wire October 19, 2023

Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy

Business Wire October 16, 2023

Omeros Corporation Reports Second Quarter 2023 Financial Results

Business Wire August 9, 2023

Omeros Corporation to Announce Second Quarter Financial Results on Morning of August 9, 2023

Business Wire August 4, 2023

Omeros Announces Webcast Details for Annual Meeting of Shareholders

Business Wire June 21, 2023

Omeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association Congress

Business Wire June 12, 2023

Omeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) Congress

Business Wire June 1, 2023

Omeros Corporation Reports First Quarter 2023 Financial Results

Business Wire May 9, 2023

Omeros Corporation to Announce First Quarter Financial Results on May 9, 2023

Business Wire May 4, 2023

Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria

Business Wire April 25, 2023

Omeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction Program

Business Wire April 10, 2023

Omeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results

Business Wire March 13, 2023